Stocktoria
Cullinan Therapeutics, Inc. CGEM
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-08
Chart by TradingView
1/9
Piotroski F — financial health
8.03
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | — | $0 | $18.9M |
| Operating income | -$241.6M | -$196.9M | -$191.1M | $144.6M | -$68.0M |
| Net income | -$219.9M | -$167.4M | -$153.2M | $111.2M | -$65.6M |
| Operating cash flow | -$175.8M | -$145.3M | -$134.3M | -$126.7M | -$43.4M |
| Free cash flow | -$175.8M | -$145.3M | -$134.5M | -$127.8M | -$43.4M |
| Total assets | $448.4M | $621.8M | $484.2M | $561.1M | $437.2M |
| Total liabilities | $39.6M | $31.5M | $30.3M | $26.1M | $11.8M |
| Shareholders' equity | $408.7M | $590.3M | $453.9M | $535.0M | $425.4M |
| Ratios | |||||
| Operating margin | — | — | — | — | -358.7% |
| Net margin | — | — | — | — | -346.1% |
| FCF margin | — | — | — | — | -229.3% |
| Return on assets | -49.0% | -26.9% | -31.6% | 19.8% | -15.0% |
| Return on equity | -53.8% | -28.4% | -33.7% | 20.8% | -15.4% |
| Current ratio | 10.25 | 13.53 | 17.07 | 21.09 | 25.25 |
| Revenue growth | — | — | — | -100.0% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 905,376 | $12.9M |
| RENAISSANCE TECHNOLOGIES LLC | 324,111 | $4.6M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 8.03 (safe)
- Working capital / assets 0.778
- Retained earnings / assets -1.312
- EBIT / assets -0.539
- Equity / liabilities 10.31
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001789972 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.